On September 2, 2025, Opus Genetics, Inc. announced the appointment of Rob Gagnon, CPA, MBA, as its new Chief Financial Officer. Mr. Gagnon brings over two decades of financial and operational leadership experience in both public and private companies.
Mr. Gagnon has a track record of raising over $2 billion in capital, executing multiple strategic transactions, and guiding companies through IPOs, late-stage clinical development, commercial launches, and M&A. His expertise is expected to be invaluable as Opus Genetics advances its clinical pipeline and prepares for multiple regulatory milestones.
Prior to joining Opus, Mr. Gagnon served as CFO at Remix Therapeutics and held senior finance leadership roles at Verastem Oncology, Harvard Bioscience, Clean Harbors, and Biogen. His appointment is seen as a move to strengthen the company's financial leadership during a pivotal growth stage.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.